Novartis initiates Phase I/II study of YTB323 in non-active Progressive Multiple Sclerosis
Novartis is conducting an open-label Phase I/II study to evaluate YTB323 in patients with non-active Progressive Multiple Sclerosis.
Asset / Drug
Drug and asset intelligence for YTB323 with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.